Liver rhabdomyosarcoma

Summary

Liver rhabdomyosarcoma (MONDO:0002849) is a disease. A subtype of liver sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	liver rhabdomyosarcoma
Mondo ID	MONDO:0002849
DOID	DOID:4047
NCIT	C5834
UMLS	C1333975
MedGen	232598
GARD	0023267
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	no

Also known as: hepatic rhabdomyosarcoma · liver rhabdomyosarcoma · liver rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of liver · rhabdomyosarcoma of liver · rhabdomyosarcoma of the liver

Disease family

This is a subtype of liver sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › liver sarcoma › liver rhabdomyosarcoma

Related subtypes (6): liver angiosarcoma, bile duct sarcoma, liver leiomyosarcoma, liver extraskeletal osteosarcoma, liver fibrosarcoma, undifferentiated (embryonal) sarcoma

Subtypes (1): extrahepatic bile duct rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.